gene_symbol
FCGR2A
hgnc_id
HGNC:3616
binding_type
receptor ligand recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
Naxitamab binds GD2 on tumor cells; its Fc engages Fcγ receptors (including CD32A) on immune cells to drive ADCC/ADCP and complement activation, killing GD2-positive cells rather than CD32A-expressing cells.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
Macrophage Fc receptor contributing to ADCP
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06574698
disease_id_num_tar_ref
546
drug_id_num_tar_ref
1505